NCT01922206

Brief Summary

The purpose of this Collaborative R01, under Program Announcement PAR-09-153, is to conduct a full-scale trial of an intervention to assist mothers living with HIV (MLH) with disclosing their serostatus to their young age 6 - 14 year old), well children. A pilot study of the intervention has recently been completed (R01 MH077493) and met its major aims. The basis for development of the pilot intervention was work from three R01s (MH057207, currently Yr. 14) designed to longitudinally assess MLH and their children. Within that work, several studies were conducted on maternal disclosure, suggesting disclosure is difficult, and outcomes for MLH and children could be improved by intervention. The pilot study, known in the community as Teaching, Raising, And Communicating with Kids (TRACK), was based on integrative disclosure theory. Results of the pilot trial indicate that those in the intervention group were six times more likely to disclose their HIV/AIDS status to their child than those in the control group (O.R. 6.33); by the 9-month follow-up 33% of intervention MLH disclosed, compared to only 7.3% of the control group. Perhaps more importantly, the intervention group's emotional functioning and their satisfaction improved significantly following the intervention, compared to the control group. Similarly, child mental health indicators among children of intervention MLH were significantly better than control group children at follow-ups. In this study, TRACK II, we propose to conduct a full-scale trial of the intervention in two sites: (1) Los Angeles county (Site 1, where the pilot trial was conducted), which will include a high proportion of Latina families and a smaller proportion of African-American and White families; and (2) Atlanta, Georgia (Site 2, where the primary consultant on the pilot trial conducts research), which will include a high proportion of Southern African-American families, as well as White families. MLH and their children (N = 440 total; 110 mothers and 110 children per site, n = 220 per site) will be assessed at baseline and at 3, 9, and 15-month follow-ups. MLH will be randomly assigned to the intervention or control. Aims are to:

  1. 1.facilitate disclosure of the mothers' HIV status to the children, which will include secondary aims of:
  2. 2.increasing mothers' self-efficacy to disclose and respond to child questions regarding HIV;
  3. 3.reducing mothers' fears regarding disclosure and stigma;
  4. 4.improving maternal knowledge of child development and how to provide appropriate levels of information given the age of the child;
  5. 5.improve MLH mental health indicators over time (i.e., depression, anxiety, quality of life);
  6. 6.improve child mental health indicators over time (i.e., depression, anxiety, acting out behaviors); and
  7. 7.improve family functioning indicators (e.g., cohesion, perceived closeness between mother and child).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
362

participants targeted

Target at P50-P75 for not_applicable hiv

Timeline
Completed

Started Mar 2013

Longer than P75 for not_applicable hiv

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

August 2, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

August 14, 2013

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
Last Updated

January 18, 2020

Status Verified

January 1, 2020

Enrollment Period

4.7 years

First QC Date

August 2, 2013

Last Update Submit

January 14, 2020

Conditions

Keywords

HIVMaternal Disclosure

Outcome Measures

Primary Outcomes (1)

  • Disclosure of Maternal HIV status to child

    Change in disclosure status between time points 3-, 9-, & 15 month follow ups

Secondary Outcomes (1)

  • Child Mental Health Functioning (Composite measure)

    15- month follow up

Other Outcomes (2)

  • Maternal Functioning (composite measure)

    15 month follow-up

  • Family functioning (composite measure)

    15 month follow-up

Study Arms (2)

Wait-list Control

NO INTERVENTION

Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.

TRACK Intervention

EXPERIMENTAL

3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child

Behavioral: TRACK Intervention

Interventions

TRACK Intervention 3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child

TRACK Intervention

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Mother is HIV+
  • ability of mother and child to speak and understand English or Spanish
  • child is not HIV+
  • Child is 6-14 years old
  • Child is unaware of maternal HIV status
  • child resides with mother

You may not qualify if:

  • Mother does not consent
  • Child does not assent
  • Psychosis of mother or child
  • Child diagnosed with depression
  • child is developmentally delayed
  • Recent or anticipated death in the family

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Georgia State University

Atlanta, Georgia, 30302, United States

Location

Related Publications (2)

  • Marelich WD, Ali B, Murphy DA, Schulte MT, Armistead L. Predictors of serostatus nondisclosure in mothers living with human immunodeficiency virus receiving a disclosure intervention: Analysis of a randomized clinical trial intervention arm. Health Psychol. 2024 Sep;43(9):663-672. doi: 10.1037/hea0001390. Epub 2024 Apr 25.

  • Schulte MT, Armistead L, Murphy DA, Marelich W. Multisite longitudinal efficacy trial of a disclosure intervention (TRACK) for HIV+ mothers. J Consult Clin Psychol. 2021 Feb;89(2):81-95. doi: 10.1037/ccp0000622.

Study Officials

  • Lisa P Armistead, Ph.D.

    Georgia State University

    PRINCIPAL INVESTIGATOR
  • Debra Murphy, Ph.D.

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Distinguished Professor

Study Record Dates

First Submitted

August 2, 2013

First Posted

August 14, 2013

Study Start

March 1, 2013

Primary Completion

November 1, 2017

Study Completion

November 1, 2019

Last Updated

January 18, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will share

Data sharing protocols for the longitudinal data from 220 young children and 220 mothers will be in accordance with NIH Notice of Amendment to A-110, consistent with IRB-approved consent restrictions, and follow Inter-University Consortium for Political and Social Research guidelines for data preparation. Data will be stripped of identifiers and available under signed agreement for: (1) using data only for research; (2) securing date using appropriate technology; and (3) destroying or returning data after analyses. Notice of available data will be on both centers' websites, with data use restrictions.

Locations